CRLF2 rearrangements are a new prognostic marker for BCP-ALL, and the inhibition of JAK/STAT5 signaling represents a potential new therapeutic approach for this subgroup of patients. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.